Literature DB >> 9424978

Hydroxyurea-induced leg ulceration in 14 patients.

P J Best1, M S Daoud, M R Pittelkow, R M Petitt.   

Abstract

BACKGROUND: Hydroxyurea is an antineoplastic agent commonly used to treat myeloproliferative disorders and other nonneoplastic conditions.
OBJECTIVE: To further define the typical features of hydroxyurea-related cutaneous ulcers of the leg.
DESIGN: Retrospective, descriptive study of the medical records of patients who developed leg ulcers while receiving hydroxyurea therapy.
SETTING: A tertiary care medical center. PATIENTS: Patients with myeloproliferative disorders who were treated with hydroxyurea.
RESULTS: 14 patients with extremely painful leg ulcers were identified. The most common ulcer site was the malleoli. Multiple ulcers were seen in 64% of patients. Patients had received hydroxyurea for an average of 6 years before ulcers developed. All ulcers healed after discontinuation of hydroxyurea treatment, and 2 patients developed ulcers after treatment was restarted.
CONCLUSION: Hydroxyurea induces painful leg ulcers that are usually difficult to treat and require cessation of hydroxyurea therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9424978     DOI: 10.7326/0003-4819-128-1-199801010-00005

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  17 in total

1.  [Painful symmetrical ankle ulcerations. A 73-year old patient with chronic myeloid leukemia].

Authors:  K Welt; S Ott; J M Weiss; K Scharffetter-Kochanek
Journal:  Hautarzt       Date:  2004-02       Impact factor: 0.751

Review 2.  Vasculitic and autoimmune wounds.

Authors:  Victoria K Shanmugam; Divya Angra; Hamza Rahimi; Sean McNish
Journal:  J Vasc Surg Venous Lymphat Disord       Date:  2016-12-14

3.  A Hydroxyurea-induced Leg Ulcer.

Authors:  Seon-Wook Hwang; Soon-Kwon Hong; Sang-Hyun Kim; Jong-Keun Seo; Deborah Lee; Ho-Suk Sung
Journal:  Ann Dermatol       Date:  2009-02-28       Impact factor: 1.444

Review 4.  The therapy of myelofibrosis: targeting pathogenesis.

Authors:  Ruben A Mesa
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 5.  What is the standard treatment in essential thrombocythemia.

Authors:  Tiziano Barbui
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

6.  Chronic leg ulceration associated with polycythemia vera responding to ruxolitinib (Jakafi(®)).

Authors:  Victoria K Shanmugam; Sean McNish; Nawar Shara; Katherine J Hubley; Bhaskar Kallakury; David M Dunning; Christopher E Attinger; John S Steinberg
Journal:  J Foot Ankle Surg       Date:  2013-08-14       Impact factor: 1.286

Review 7.  Polycythaemia vera and essential thrombocythaemia in the elderly.

Authors:  P J van Genderen; M M Troost
Journal:  Drugs Aging       Date:  2000-08       Impact factor: 3.923

8.  Vasculitic Diseases and Prothrombotic States Contributing to Delayed Healing In Chronic Wounds.

Authors:  Victoria K Shanmugam
Journal:  Curr Dermatol Rep       Date:  2016-09-09

Review 9.  [Ulcers following therapy with hydroxyurea. Three case reports and review of the literature].

Authors:  S Boneberger; R A Rupec; T Ruzicka
Journal:  Hautarzt       Date:  2010-07       Impact factor: 0.751

10.  Hydroxyurea induced perimalleolar ulcers.

Authors:  Kavitha Saravu; Praveen Velappan; Naik Lakshmi; Barkur Ananthakrishna Shastry; Joseph Thomas
Journal:  J Korean Med Sci       Date:  2006-02       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.